Additional Information

Description

Lynparza (Olaparib) 150 mg Tablets, 120/Ea is a poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain cancers associated with BRCA mutations and homologous recombination repair (HRR) deficiencies. It is indicated for patients with advanced ovarian, breast, pancreatic, and prostate cancers who meet specific genetic and clinical criteria. By inhibiting PARP enzymes, it prevents DNA repair in cancer cells, leading to cell death and reduced tumor progression.

Lynparza is administered orally in a recommended dose of 300 mg (two 150 mg tablets) twice daily, totaling 600 mg per day. The tablets should be swallowed whole and not chewed, crushed, or split. Dosing adjustments may be required for patients with renal impairment or those experiencing severe adverse effects. It can be taken with or without food, and consistency in administration timing is recommended for optimal therapeutic effect.

Common adverse effects include nausea, fatigue, anemia, vomiting, diarrhea, and decreased appetite. Serious risks include myelodysplastic syndrome, acute myeloid leukemia, pneumonitis, and severe bone marrow suppression. Regular monitoring of complete blood counts (CBC), renal function, and liver enzymes is necessary during treatment to assess for toxicity.